Alpha-actinin-4 mRNA (ACTN4 mRNA) (ACTN4 mRNA)

Alpha-actinin-4 (ACTN4) is a member of the spectrin gene superfamily, primarily known for its role as an actin-binding protein that cross-links F-actin into bundles (UniProt P35609). Beyond its cytoskeletal functions, ACTN4 can translocate to the nucleus where it acts as a transcriptional co-activator for various signaling pathways, including the Wnt/beta-catenin and NF-kappaB pathways (PMID: 25983578). In the context of oncology, ACTN4 mRNA is frequently overexpressed, correlating with increased cell motility, invasion, and poor prognosis in cancers such as pancreatic, breast, and colorectal carcinoma (PMID: 25983578, PMID: 26261558). Additionally, mutations in the ACTN4 gene are a known cause of familial focal segmental glomerulosclerosis (FSGS), a condition characterized by progressive kidney scarring (PMID: 10746727). Therapeutic strategies targeting ACTN4 mRNA, such as small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs), aim to downregulate protein expression to inhibit metastatic progression or manage podocyte dysfunction (PMID: 25983578). While currently primarily in the preclinical stage, ACTN4 mRNA represents a promising target for precision medicine in both oncology and nephrology.

Other names

ACTN4Alpha-actinin-4FSN1Non-muscle alpha-actinin 4

RNA interference (siRNA) or antisense oligonucleotide (ASO) mediated degradation of mRNA to reduce protein expression.